|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of injection moulding conditions on knit line formation显示文摘 | PICCAROLO S RALLIS A TITOMANLIO G | 1987 | Plastics and Rubber Processing and Application1987，8，3： | 1 |
| 2 | Beyond naming patterns in children with word finding difficulties-Definitions for nouns and verbs显示文摘 | Dockrell J Messer D George R Ralli A | | 0，，16： | 1 |
| 3 | Tactical allocation in commodity futures markets: combining momentum and term structure signals显示文摘 | Fuertes A M Miffre J Rallis G | 2010 | Journal of Banking & Finance2010，34，： | 1 |
| 4 | Laminar Burning Velocity of Stoichiometric Methane-Air: Pressure and Temperature Dependence显示文摘 | Garforth A M Rallis C J | 1978 | Combustion and Flame1978，31，： | 1 |
| 5 | Effect of injection molding conditions on knit-line formation显示文摘 | Piccarolo S Rallis A Titomanlio G | 1987 | Plas Rubber Proc Appl1987，8，3： | 1 |
| 6 | Effect of injection moulding conditions on knit-line formation 显示文摘 | Piccarolo S Rallis A Titomanlio G | 1987 | Plastics and Rubber Processing and Applications1987，8，3： | 1 |
| 7 | Effect of injection moulding conditions on knit - line formation 显示文摘 | PICCAROLO S RALLIS A TITOMANLIO G | 1987 | Plastics and Rubber Processing and Applications1987，8，3： | 1 |
| 8 | Pimecrolimus cream 1% can be an effective treatment for seborrhei c dermatitis of the face and trunk显示文摘 | Nasiopoulou A Kouskoukis C | 2004 | DrugS ExP Clin Res2004，30，56： | 1 |
| 9 | The monitoring role of otoacoustic emissions and oxidative stress markers in the protec- tive effects of antioxidant administration in noise - exposed subjects : A pilot study显示文摘 | FETONI A R GARZARO M RALLI M | 2009 | Med Sci Monit2009，15，11： | 1 |
| 10 | Oxcarbazepineinduced localized penile edema显示文摘 | Rallis E Theodoridis A Moussatou V | 2005 | J Dtsch Dermatol Ges2005，3，10： | 1 |
| 11 | Molecular chaperones protect a- gainst JNK- and Nmnat-regulated axon degeneration in Dro- sophila显示文摘 | Rallis A Lu BW Ng J | 2013 | J Cell Sci2013，126，3： | 1 |
| 12 | Iron, zinc, and copper concentration in serum, various organs, and hair of dogs with experimentally induced exocrine pancreatic insufficiency显示文摘 | Admama M K Rallis T Papasteriadis A Roubies N Kaldrimidou H | 2001 | Digestive Disease and Science2001，7，： | 1 |
| 13 | Survivin -- 31G/C promoter polymorphism and sporadic eolorectal cancer显示文摘 | Gazouli M Tzanakis N Rallis G Theodoropoulos G Papaconstantinou I Kostakis A | 2009 | Int J Colorectal Dis2009，24，： | 1 |
| 14 | Radio frequency identification (RFID) in healthcare:a literature review显示文摘 | Kolokathi A Rallis P | 2013 | Stnd Health TechnolInform2013，190，1： | 1 |
| 15 | Effect of injection moulding condition on kint-line formation显示文摘 | Piccarolo S Rallis A Titomanlio G | 1997 | Plas Rubber Prec and Appl1997，8，3： | 1 |
| 16 | Effect of injection moulding condition on kint-line formation显示文摘 | Piccarolo S Rallis A Titomanlio G | 1997 | Plas Rubber Prec and Appl1997，8，3： | 1 |
| 17 | Effect of injection moulding conditions on knit line formation显示文摘 | Piecarolo S Rallis A Titomanlio G | 1987 | Plastics and Rubber Proceessing and Applications1987，8，3： | 1 |
| 18 | Immunotherapy for advanced hepatocellular carcinoma:From clinical trials to real-world data and future advances显示文摘Hepatocellular carcinoma(HCC)is a leading cause of cancer-associated mortality worldwide.HCC is an inflammation-associated immunogenic cancer that frequently arises in chronically inflamed livers.Advanced HCC is managed with systemic therapies;the tyrosine kinase inhibitor(TKI)sorafenib has been used in 1st-line setting since 2007.Immunotherapies have emerged as promising treatments across solid tumors including HCC for which immune checkpoint inhibitors(ICIs)are licensed in 1st-and 2nd-line treatment setting.The treatment field of advanced HCC is continuously evolving.Several clinical trials are investigating novel ICI candidates as well as new ICI regimens in combination with other therapeutic modalities including systemic agents,such as other ICIs,TKIs,and anti-angiogenics.Novel immunotherapies including adoptive cell transfer,vaccine-based approaches,and virotherapy are also being brought to the fore.Yet,despite advances,several challenges persist.Lack of real-world data on the use of immunotherapy for advanced HCC in patients outside of clinical trials constitutes a main limitation hindering the breadth of application and generalizability of data to this larger and more diverse patient cohort.Consequently,issues encountered in real-world practice include patient ineligibly for immunotherapy because of contraindications,comorbidities,or poor performance status;lack of response,efficacy,and safety data;and cost-effectiveness.Further real-world data from high-quality large prospective cohort studies of immunotherapy in patients with advanced HCC is mandated to aid evidence-based clinical decision-making.This review provides a critical and comprehensive overview of clinical trials and real-world data of immunotherapy for HCC,with a focus on ICIs,as well as novel immunotherapy strategies underway. | Kathrine S Rallis Dimitrios Makrakis Ioannis A Ziogas Georgios Tsoulfas | 2022 | World Journal of Clinical Oncology2022，13，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员